

- structure of, 96e-2f
 supplements. *See* Folate supplements
 systems analysis of effects of, 87e-3
 transport in blood, 641
- Folate deficiency. *See also* Megaloblastic anemia
 anemia in, 398
 causes of, 646-647, 646f
 clinical features of, 96e-1t, 461, 642-643
 diagnosis of, 647-648
 hematologic findings in, 643-644
 neural tube defects and, 642-643
 neutrophil segmentation in, 415
 optic neuropathy in, 203
 peripheral blood smear in, 81e-3f
 in pregnancy, 265e-12, 642-643, 646
 in premature infants, 647
 prophylaxis for, 647-648
 psychiatric disturbance in, 643
 skin manifestations of, 360
 small-intestinal mucosal biopsies in, 1940t
 treatment of, 461, 647
- Folate supplements
 for colorectal cancer prevention, 539
 in infants and children, 649
 for methotrexate toxicity prophylaxis, 2182
 for paroxysmal nocturnal hemoglobinuria, 661
 in pregnancy, 29t, 47, 642, 648-649
 prophylactic, 648
 for pyruvate kinase deficiency, 654
 for thalassemia, 638
 for tropical sprue, 1943
- Folate synthesis antagonists, 931t, 932, 932f
- FOLFIRINOX regimen, 557, 557t
- FOLFIRI regimen, 543
- FOLFOX regimen, 543
- Folic acid, 640. *See also* Folate
- Folinic acid
 for folate deficiency, 648
 for megaloblastic anemia prophylaxis, 903
 for methotrexate toxicity prophylaxis, 2182
 for pancreatic cancer, 556t, 557
- Follicle(s)
 Graafian, 2376f
 ovarian, 2375f, 2376, 2376f
- Follicle-stimulating hormone (FSH)
 action of, 401e-4
 deficiency of, 2259t
 expression and regulation of, 401e-1t
 in females, age-related changes in levels of, 2376-2377, 2377f
 laboratory evaluation of, 2258t, 2760t
 in male pubertal development, 2358
 in menstrual cycle regulation, 2378-2379, 2378f, 2379f
 in ovarian follicle development, 2375f, 2376
 in perimenopause, 2381, 2381f
 secretion of, 401e-4
 in spermatogenesis, 2359-2360
 synthesis of, 401e-4
- Follicle-stimulating hormone (FSH) receptor, 437
- Follicle-stimulating hormone (FSH) therapy, 337, 2369
- Follicular dendritic cell(s), 135e-9, 1232
- Follicular lymphoma, **704**
 clinical features of, 702t, 704
 epidemiology of, 704
 genetic considerations in, 101e-3t, 699t, 704
 immunology of, 698, 698f
 lymph node examination in, 81e-10f, 704f
 transformation to diffuse B-cell lymphoma, 705
 treatment of, 704-705
 tumor markers in, 135e-2t
- Folliculitis, **356**
Candida, 1343
 clinical features of, 341t, 342f
 eosinophilic, 356
 etiology of, 828t, 829
 in HIV infection, 1262-1263
 hot-tub, 131t, 134, 356, 829, 1047
Malassezia, 1357
- Folliculitis decalvans, 355, 355t
- Fomepizole, 64e-9, 319, 1777
- Fomivirsen, 215e-2t, 215e-7-8, 215e-8
- Fondaparinux, **752**
 action of, 750f, 753
 adverse effects of, 753
 for antiphospholipid antibody syndrome, 2136
 for DVT/PE treatment, 1635, 1635t
 for heparin-induced thrombocytopenia, 728
 vs. low-molecular-weight heparin, 753t
 for myocardial infarction, 1597, 1598t
 pharmacology of, 753
 for VTE prophylaxis, 55, 1637t
- Fonsecaea*, 1355
- Food exchange list, 95e-5
- Food frequency questionnaire, 95e-5
- Food guide, 95e-5
- Food insecurity, 461
- Food intake, in obesity, 415e-5
- Food-related illness
 bacterial, 855-856, 856t
B. cereus, 856, 856t
C. botulinum, 987-988
C. jejuni. *See* *Campylobacter* spp. infections
C. perfringens, 856, 856t, 991
E. coli. *See* *Escherichia coli* infections, intestinal
L. monocytogenes, 266, 983
 non-01/039 *V. cholera*, 1065-1066, 1065t
S. aureus. *See* *Staphylococcus aureus* infections, food-borne
Salmonella. *See* *Salmonella* spp. infections, gastroenteritis
Shigella. *See* *Shigella* spp. infections
V. cholerae. *See* Cholera
V. parahaemolyticus, 856t, 1065, 1065t
V. vulnificus, 782, 1065t, 1066
 ciguatera poisoning, 2742
 diarrhea in, 266, 855-856, 856t. *See also* Diarrhea, infectious
 diarrhetic shellfish poisoning, 2742-2743
 differential diagnosis of, 266, 266t
 domoic acid intoxication, 2743
 nematode-borne. *See* Nematodes/nematode infections
 paralytic shellfish poisoning, 2743
 scombroid poisoning, 2743-2744
 viral, 266t, 855
- Food webs, 86e-5
- Foot drop, 463e-4, 1124
- Foot examination, in diabetes mellitus, 2407
- Foot osteomyelitis, 845, 845f
- Foramen magnum syndrome, 2652
- Foramen ovale, 1520
- Foraminal herniation, 1772, 1772f
- Forbes syndrome (type IIIa GSD), 433e-2t, 433e-3
- Forced expiratory volume in 1 s (FEV₁), 306e-5f, 306e-6
- Forced vital capacity (FVC), 306e-5f, 306e-6
- Forchheimer spots, 127
- Fordyce spots, 127, 240t
- Forearm exercise test, 462e-5
- Foreign body
 aspiration of, 1768
 in esophagus, 1891-1892, 1893f, 1911
 in eye, 199
 granuloma, 367
- Formaldehyde exposure, 345, 1692t
- Formalin-ether sedimentation, 152e-1
- Formiminoglutamic aciduria, 434e-2t
- Formoterol, 1705
- 10-Formyl (CHO)tetrahydrofolate, 641t
- Fortification spectra, 204, 2535
- Fort Sherman virus, 1308t
- "Forward type," 138e-2
- Fosamprenavir, 1278, 1280f
- Foscarnet
 action of, 215e-8, 897
 adverse effects of
 electrolyte disturbances, 215e-8-9, 1193-1194
 hypokalemia, 306
 nephrotoxicity, 215e-8, 897, 1193-1194, 1804
- for CMV infection, 215e-2t, 215e-8, 922, 1193-1194, 2657
 for CMV prophylaxis in HIV infection, 1252t
 for HHV-6 infections, 215e-8, 922
 for HSV infections, 215e-8, 1182, 1182t
 for viral encephalitis, 897
- Fosfomycin
 action of, 930, 931t, 944
 adverse effects of, 938t, 944
 for *Citrobacter* infections, 1035
 indications for, 941t, 944
 for *Proteus* infections, 1034
 resistance to, 931t, 944
 for urinary tract infections, 866, 867t, 975t, 1029
- FOS gene mutations, 101e-2t
- Fosphenytoin, 1735
- Foster Kennedy syndrome, 216
- Founder effect, 435
- Fournier's gangrene, 831, 1099, 2199
- Fovea, 40e-1, 195
- Foveation, 195
- Foville's syndrome, 209
- Foxglove, 310, 473e-9t
- FOXJ2 gene mutations, 594
- FOXO3A gene, 94e-4
- FOXP3, 377e-2, 2113, 2141, 2348
- FOXP3 gene mutations, 2348
- Fractalkine, 372e-13t
- Fractional excretion of sodium (FeNA), 1807
- Fractional flow reserve (FFR), 296e-4, 1465
- Fracture(s)
 atypical femur, 2501, 2501f
 Colles', 2488f
 hip. *See* Hip(s), fracture of
 hyponatremia and, 301
 IBD-related, 1958
 Lisfranc, 2244
 odontoid, 441e-33f
 in osteogenesis imperfecta, 2508
 osteoporotic. *See* Osteoporosis, fractures in
 Paget's disease of bone and, 426e-2
 pelvic, 2489
 risk assessment for, 2495-2496, 2496f
 skull, 457e-2
 teardrop, 441e-34f
 temporal bone, 220
 vertebral. *See* Vertebral fractures
 wrist, 2489
- Fragile X pre-mutation, 163
- Fragile X syndrome, 336, 434, 440t, 465e-1
- Fragile X tremor/ataxia syndrome, 451e-3t
- Frailty
 assessment of, 78-79, 78t
 consequences of, 77-79
 definition of, 77
 falls and, 163
 model of, 73f
 severity of, 77
- Framboesia. *See* Yaws
- Frameshift mutation, 432
- Framework Convention on Tobacco Control (WHO), 17
- Francisella* spp., 1066-1067
- Francisella tularensis*, 261e-7, 1066-1067. *See also* Tularemia
- Franklin's disease (gamma heavy chain disease), 718
- Frasier's syndrome, 2353
- Frataxin* gene, 2630
- Fraudulent fever, 138
- FRAX tool, for fracture risk assessment, 2495-2496, 2495f
- FRC (functional residual capacity), 306e-2, 306e-5f, 306e-6, 1733
- Freckles (ephelides), 359
- Free erythrocyte protoporphyrin, 2525
- Free fatty acids (FFAs)
 in cardiac metabolism, 265e-10
 in glucose utilization, 2405
 in insulin resistance, 2450, 2451f
 reference values for, 2760t
- Free radical theory of aging, 94e-3
- Free T₃ index, 2288